文献速递白血病淋巴瘤

内皮细胞与白血病相互作用重塑药物反应并揭示T-ALL脆弱性

Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.
PubMed 文献 · Blood · 2023-01-01

研究建立T-ALL患者来源肿瘤异种移植(PDX)模型,用433种临床阶段化合物筛选出39种抗白血病活性药物,并构建内皮细胞(EC)/T-ALL共培养体系,发现EC提供促肿瘤信号并减弱药物反应,共培养T-ALL细胞转录组模拟体内脾脏T-ALL,5种有效药物在体内延缓肿瘤生长并延长总生存。

要点

  • 433种临床阶段化合物筛出39种广谱抗白血病活性药物
  • 内皮细胞提供促肿瘤信号并减弱T-ALL PDX药物反应
  • 5种有效药物体内延缓肿瘤生长与播散并延长总生存

核心结论

  • 研究建立T-ALL/EC平台,阐明白血病-微环境相互作用并识别有效化合物和治疗脆弱性。

研究设计与样本

  • 研究先建立T-ALL患者来源肿瘤异种移植(PDX)模型,并将PDX细胞体外暴露于433种临床阶段化合物库。
  • 研究建立内皮细胞(EC)/T-ALL共培养体系,并在单细胞水平分析共培养T-ALL细胞与EC的转录组变化。
  • 研究从2次药物筛选中选出5种有效药物进行体内测试。

主要发现

  • 体外筛选鉴定出39种具有抗白血病活性的广谱活性药物。
  • ECs提供促肿瘤信号并减弱T-ALL PDX的药物反应。
  • ECs在多数模型中广泛挽救数种化合物,而对某些药物的挽救仅限于个别PDX,提示独特串扰相互作用和/或内在肿瘤特征。
  • 共培养的T-ALL细胞与ECs在单细胞水平发生双向转录组变化,呈现不同的「教育特征」,与T-ALL细胞及ECs中多条通路的双向调控相关。
  • 体外EC教育的T-ALL细胞在单细胞分辨率下转录组模拟离体脾脏T-ALL。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and often incurable disease. To uncover therapeutic vulnerabilities, we first developed T-ALL patient-derived tumor xenografts (PDXs) and exposed PDX cells to a library of 433 clinical-stage compounds in vitro. We identified 39 broadly active drugs with antileukemia activity. Because endothelial cells (ECs) can alter drug responses in T-ALL, we developed an EC/T-ALL coculture system. We found that ECs provide protumorigenic signals and mitigate drug responses in T-ALL PDXs. Whereas ECs broadly rescued several compounds in most models, for some drugs the rescue was restricted to individual PDXs, suggesting unique crosstalk interactions and/or intrinsic tumor features. Mechanistically, cocultured T-ALL cells and ECs underwent bidirectional transcriptomic changes at the single-cell level, highlighting distinct "education signatures." These changes were linked to bidirectional regulation of multiple pathways in T-ALL cells as well as in ECs. Remarkably, in vitro EC-educated T-ALL cells transcriptionally mirrored ex vivo splenic T-ALL at single-cell resolution. Last, 5 effective drugs from the 2 drug screenings were tested in vivo and shown to effectively delay tumor growth and dissemination thus prolonging overall survival. In sum, we developed a T-ALL/EC platform that elucidated leukemia-microenvironment interactions and identified effective compounds and therapeutic vulnerabilities.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cappelli LV, Fiore D, Phillip JM, et al. Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities. Blood. 2023. PMID: 35981563. doi:10.1182/blood.2022015414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。